Fairvalue-Calculator Fairvalue-Calculator
EN DE

Amneal Pharmaceuticals, Inc (AMRX) Fair Value & Analysis

Healthcare · US · Market cap $4.3B

Price$16.66
Fair Value$9.64
Upside-42.1%
Quality92/100
Evidence: High Range $3.83 – $14.81

Fair value as of: Jun 24, 2026

Analysis

Amneal Pharmaceuticals, Inc (AMRX) currently trades at $16.66, while our model-based Fair Value estimate is $9.64 — implying the stock looks roughly 42.1% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroi…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Amneal Pharmaceuticals, Inc (AMRX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $9.64 versus a price of $16.66 — about −42% (overvalued). Model-based estimate, not financial advice.
What is the fair value of AMRX?
Our 21-model fair value for Amneal Pharmaceuticals, Inc is $9.64 (as of Jun 24, 2026), built from audited fundamentals. The current price is $16.66.
What is the quality score of AMRX?
Amneal Pharmaceuticals, Inc has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.